Objective To observe the effects of Xuezhikang on blood lipids and the levels of plasma endothelins, thromboxane B2, 6-keto-PGFla in patients with primary hyperlipidaemia.
Methods 120 patients with primary hyperlipidaemia were enrolled in this study, 82 males and 38 females, age 36–74 years old, average ages (55±9) years old. 12 weeks after taking Xuezhikang, the clinical effect and the effect on the level of plasma endothelins, thromboxane B2, 6-Keto-PGFla were compared before and after the treatment, and the relation between blood lipids and ratio of plasma endothelins, thromboxane B2 to 6-Keto-PGFla were analysed.
Results 12 weeks after treatment, the level of TG, cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and apoB100 decreased sharply (p<0.05–0.001); the level of serum high density lipoprotein cholesterol (HDL-C) elevated (p<0.05); ratio of plasma endothelins decreased sharply (p<0.001); rate value of thromboxane B2 to 6-Keto-PGFla before treatment was higher than health people but lower after treatment (p<0.01). There were positive correlations between the decreased TC. TG, LDL-C and decreased ET-1, the ratio TXB2/6-keto-PGFla (r=0.832–0.963, p<0.01–0.001). The same positive correlation was found between the decreased ET-1 and the ratio of TXB2/6-keto-PGF1a (r=0.987, p<0.001).
Conclusions Plasma endothelins level and ratio of thromboxane B2 to 6-Keto-PGFla increased in the patients with primary hyperlipidaemia. Xuezhikang not only effectively adjusted blood lipids level but also reduced plasma endothelins level and ratio of thromboxane B2 to 6-Keto-PGFla.
- Cholesterol (TC)
- low density lipoprotein cholesterol (LDL-C)
- high density lipoprotein cholesterol (HDL-C)